

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 11:14:21 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: the Strategy document
Attachments: COVID vaccine editorial_prefinal April19 wfigure.docx

Email below is from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Corey MD, Larry (b) (6) >
Sent: Sunday, April 19, 2020 11:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Cc: Mascola, John (NIH/VRC) [E] (b) (6) >; Miner PhD, Mindy <(b) (6)>
Subject: the Strategy document

Here is the working draft of the article for the NEJM . It , in my opinion, reads really well . I have embellished it today with a figure that conceptually outlines what we are talking about ; the old axiom that a picture is worth a thousand words .

The editorial guidelines of the NEJM has 2 potential categories . One is Perspectives which is 1200 words an 5 references . We are at 1750 words and I think losing 500 words takes away a lot from the message . The other category is a special report which is over 2500 words and allows lots of references (40) I think this is best and was one reason I thought about adding the conceptual figure which does outline in a single picture what we are talking about .

Tony , If you feel its best to have Francis on this paper we both support it . Your call . I do however lean on including Francis . I would say politicly to achieve our goal and bring all these companies into the tent while you are away at the White House having him buy into this plan through the ACTIV program seems important to us . I think we get to our goal if he is out there publicly embracing this; using the NIAID networks labs DSMB and the correlates programs . This type of granularity really puts him deep into understanding what we are doing . If this means you are first and he is last author we are ok with that , For me I need to have him use me for interfacing with the company in defining these collaborations . If you were present all the time this would be unnecessary , but as he will be the link with BARDA linking him to John and I increases the likelihood of success.